Join the club for FREE to access the whole archive and other member benefits.

Athersys

Biotechnology company

Athersys, Inc., based in Cleveland, Ohio, is a leading biotechnology company specializing in regenerative medicine. Founded in 1995, the company is best known for its innovative MultiStem® platform, an off-the-shelf stem-cell-based therapy designed to enhance tissue repair and regulate immune responses. MultiStem’s unique approach allows scalable production and eliminates the need for donor-recipient matching, making it accessible for a broad range of patients. Athersys is targeting critical unmet medical needs in areas like ischemic stroke, acute respiratory distress syndrome (ARDS), and graft-versus-host disease (GvHD), where conventional treatments often fall short.

The company is advancing MultiStem through rigorous clinical trials, including late-stage studies, while leveraging strategic global collaborations to expedite development. Notably, its work in Japan under the Sakigake Designation aims to accelerate approval for transformative therapies. With a commitment to addressing life-threatening conditions and improving patient outcomes, Athersys is poised to redefine how regenerative medicine is applied in modern healthcare.

Visit website: https://www.athersys.com/home/default.aspx

 Athersys

 athersys

 athersys

 UCdPx7ZXYv6oLmeyjGmqXNBQ

Details last updated 18-Nov-2024

Athersys News

Athersys faces setback as stroke therapy fails trial

Athersys faces setback as stroke therapy fails trial

FierceBiotech - 10-Oct-2023

Enrollment paused, but $1.5 million secured from new partnership

New study explores stem cell therapy for better kidney transplants

New study explores stem cell therapy for better kidney transplants

Athersys - 06-Sep-2023

Multistem aims to boost organ preservation and transplant success

Athersys advances groundbreaking trauma therapy in final trial phase

Athersys advances groundbreaking trauma therapy in final trial phase

CGTLive - 12-Jul-2023

Multistem combats inflammation to improve trauma recovery

Athersys’ stem cell therapy falls short in Japanese stroke trial

Athersys’ stem cell therapy falls short in Japanese stroke trial

FierceBiotech - 20-May-2022

Multistem shows promise in secondary measures but misses key endpoint

People at Athersys

Ellen Gurley

Manager of Corporate Communications and Investor Relations at Athersys